Drug firm Zydus Cadila and Turkey based healthcare firm, Eczacibasi Ilac Pazarlama have signed a pact to market biotech products in the Turkish market.
The collaboration agreement involves the import of biosimilars that are currently unavailable in Turkey, especially for the treatment of cancer, Zydus Group firm Cadila Healthcare said in a filing to BSE.
The pact also paves way for a long term collaboration to produce and launch new products in the market, it added.
The company however did not provide financial details of the agreement.
Zydus Group Chairman and Managing & MD Pankaj Patel said: "We are glad to partner with Eczacibasi to make available biotech therapies for patients in Turkey."
The long term agreement between both partners to enrich this collaboration through introduction of new products, will augur well for healthcare access beyond geographies, he added.
"Our target is to ensure that the important worldwide advances in the field of biotech products are simultaneously reflected and reach more people in our country and... Zydus is a very right partner in this regard," Eczacibasi Holding Chairman Bulent Eczacibasi said.
Cadila Healthcare stock was trading at Rs 319.70, up 0.19 per cent, on BSE.
